Wesana Health Holdings Inc. (WSNAF)
USD 0.01
(-72.16%)
USD 0.01
(-72.16%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.25 Million USD | 29.94% |
| 2022 | 969.06 Thousand USD | -52.19% |
| 2021 | 2.02 Million USD | 52.35% |
| 2020 | 1.33 Million USD | 18835.58% |
| 2019 | 7026.32 USD | -55.71% |
| 2018 | 15.86 Thousand USD | -82.57% |
| 2017 | 91.02 Thousand USD | 71.56% |
| 2016 | 53.06 Thousand USD | 7.72% |
| 2015 | 49.25 Thousand USD | 23.14% |
| 2014 | 40 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.07 Million USD | -6.68% |
| 2024 Q1 | 1.15 Million USD | -8.53% |
| 2023 Q4 | 1.25 Million USD | -0.49% |
| 2023 Q2 | 1.64 Million USD | 29.51% |
| 2023 Q3 | 1.26 Million USD | -22.88% |
| 2023 Q1 | 1.26 Million USD | 30.75% |
| 2023 FY | 1.25 Million USD | 29.94% |
| 2022 Q2 | 2.49 Million USD | -3.27% |
| 2022 FY | 969.06 Thousand USD | -52.19% |
| 2022 Q4 | 969.06 Thousand USD | 31.22% |
| 2022 Q3 | 738.49 Thousand USD | -70.36% |
| 2022 Q1 | 2.57 Million USD | 27.06% |
| 2021 FY | 2.02 Million USD | 52.35% |
| 2021 Q3 | 2.61 Million USD | 72.14% |
| 2021 Q4 | 2.02 Million USD | -22.42% |
| 2021 Q2 | 1.51 Million USD | -72.54% |
| 2021 Q1 | 5.52 Million USD | 315.48% |
| 2020 FY | 1.33 Million USD | 18835.58% |
| 2020 Q4 | 1.33 Million USD | 0.0% |
| 2019 FY | 7026.32 USD | -55.71% |
| 2018 FY | 15.86 Thousand USD | -82.57% |
| 2017 FY | 91.02 Thousand USD | 71.56% |
| 2016 FY | 53.06 Thousand USD | 7.72% |
| 2015 FY | 49.25 Thousand USD | 23.14% |
| 2014 FY | 40 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.262% |
| Neon Bloom, Inc. | 1.22 Million USD | -2.69% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -55.688% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2717.239% |
| Qrons Inc. | 1.48 Million USD | 15.417% |
| Rebus Holdings, Inc. | 5.24 Million USD | 75.979% |
| Skye Bioscience, Inc. | 14.07 Million USD | 91.052% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.866% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -4490.067% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.319% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -526.103% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 86.698% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.638% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 86.859% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -198.693% |
| SQZ Biotechnologies Company | 50.03 Million USD | 97.484% |
| Intellipharmaceutics International Inc. | 12 Million USD | 89.514% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 67.306% |
| Mesoblast Limited | 188.44 Million USD | 99.332% |
| Marizyme, Inc. | 26.67 Million USD | 95.28% |
| Genus plc | 485 Million USD | 99.74% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 78.448% |
| Pharming Group N.V. | 244.07 Million USD | 99.484% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 37.358% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 49.959% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 66.863% |
| ContraFect Corporation | 32.53 Million USD | 96.129% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 36.446% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 67.103% |
| IMV Inc. | 37.93 Million USD | 96.68% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 89.309% |
| MultiCell Technologies, Inc. | 1617.67 USD | -77739.918% |
| ONE Bio Corp. | 27.49 Million USD | 95.42% |
| Accustem Sciences Inc. | 1.07 Million USD | -16.674% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.373% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 40.466% |
| Q BioMed Inc. | 8.13 Million USD | 84.517% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.482% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 75.531% |
| Biomind Labs Inc. | 1.49 Million USD | 15.976% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.939% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 86.074% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 93.158% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 12.182% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -786.163% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 78.085% |
| GB Sciences, Inc. | 5.41 Million USD | 76.757% |
| Alpha Cognition Inc. | 7.16 Million USD | 82.425% |
| HST Global, Inc. | 593.59 Thousand USD | -112.131% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Halberd Corporation | 728.71 Thousand USD | -72.795% |
| Enzolytics Inc. | 365.26 Million USD | 99.655% |
| Agentix Corp. | 2.51 Million USD | 49.844% |
| Resverlogix Corp. | 67.39 Million USD | 98.132% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -50.131% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.717% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 26.535% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 94.912% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 89.421% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 65.644% |
| AVAX Technologies, Inc. | 3.99 Million USD | 68.471% |
| Zenith Capital Corp. | 27.56 Thousand USD | -4467.424% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.905% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -427.623% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 66.28% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -84.949% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 53.563% |
| Kadimastem Ltd | 3.5 Million USD | 64.073% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1781.386% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 97.495% |
| BioStem Technologies, Inc. | 15.9 Million USD | 92.083% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -170.97% |
| LadRx Corporation | 2.2 Million USD | 42.778% |
| Cell Source, Inc. | 15.8 Million USD | 92.034% |
| Regen BioPharma, Inc. | 5.45 Million USD | 76.928% |
| Regen BioPharma, Inc. | 5.45 Million USD | 76.928% |
| NovAccess Global Inc. | 7.86 Million USD | 83.981% |
| Affymax, Inc. | 8.87 Million USD | 85.806% |
| Itoco Inc. | 1.65 Million USD | 23.831% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 38.623% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 79.183% |
| Mobile Lads Corp. | 1.31 Million USD | 4.134% |
| CytoDyn Inc. | 127.89 Million USD | 99.015% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -2912.496% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 19.611% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 88.6% |
| SYBLEU INC | 681.41 Thousand USD | -84.791% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 79.364% |
| International Stem Cell Corporation | 5.27 Million USD | 76.138% |
| Bioxytran, Inc. | 3.24 Million USD | 61.25% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -101.21% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 72.728% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 96.928% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 94.345% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 37.83% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 77.014% |
| Neutra Corp. | 973.52 Thousand USD | -29.343% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 95.66% |
| PureTech Health plc | 125.58 Million USD | 98.997% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 66.485% |
| IXICO plc | 1.9 Million USD | 33.737% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 93.866% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.781% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Cellectis S.A. | 249.36 Million USD | 99.495% |